Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?
Answer from: Radiation Oncologist at Community Practice
The majority of studies suggest residual DCIS has the same outcome as pCR with no invasive disease and thus is still treated as pCR in practice.
Sign in or Register to read more
17488
Related Questions
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
When evaluating for PMRT in patients who did not receive neoadjuvant chemotherapy and are found to be pN0, do you utilize clinical T-staging, or pathologic T-staging?
What is your preferred method of surveillance after mastectomy?
Can a patient receiving post-mastectomy radiation therapy be treated concurrently with total body UVA or UVB light therapy for psoriasis?
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?
Would you offer PMRT when the only indication is a focally positive margin?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?
In a patient with otherwise favorable DCIS and a focally positive margin who refuses reexcision, is APBI an appropriate treatment option?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?